An integrative proteotranscriptomics approach reveals new ADAM9 substrates and downstream pathways
Lu, C.; Xu, X.; Sindhu, N.; Rainey, J.; Polson, S. W.; Qiu, J.; Wei, S.
Show abstract
The disintegrin metalloprotease ADAM9 is a cell-surface protease that can shed the ectodomain of membrane protein substrates. Dysregulated ADAM9 activity has been implicated in several diseases such as solid tumors, autoimmunity, inflammatory diseases, and COVID-19. Despite its importance, the substrates and targets of ADAM9 in normal and pathological processes are poorly understood. Here, we developed an integrative proteotranscriptomics approach to systematically identify the transcriptional and post-transcriptional targets of ADAM9 in HCT116 cells, which have a stable diploid karyotype suitable for omics analyses. Using this approach, we uncovered major signaling pathways downstream of ADAM9, including the oncogenic mTOR pathway and the tumor suppressor FOXO pathway. We also identified several direct and indirect substrates for ADAM9, which may mediate the pathophysiological roles of this protease. This study provides new mechanistic insights into the function of ADAM9 as well as a method that can be applied to other membrane proteases.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- ERLIN1/2 scaffolds bridge TMUB1 and RNF170 and restrict cholesterol esterification to regulate the secretory pathway 95%
- The ADAM17 sheddase complex regulator iTAP modulates inflammation, epithelial repair, and tumor growth 94%
- A phosphoproteomic approach reveals that PKD3 controls phenylalanine and tyrosine metabolism 94%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.